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CD81 is a broadly expressed molecule which was CD81 (TAPA-1) is a member of the transmembrane 4 identified originally as the target of an anti-proliferative superfamily (TM4SF) which is expressed on the cell antibody (TAPA-1) that inhibited in vitro cellular prolifersurface of most cells of the body throughout their ation (Oren et al., 1990) . In lymphocytes, CD81 has been cellular differentiation. It has been recognized in believed to be essential for B-cell development as well as several cell surface complexes of lymphocytes, sugregulating activation because it is expressed early and gesting that it may have diverse roles in lymphocyte associates with CD19, CD21 and leu13 to form a signal development and activation regulation. Mice with a transduction complex (Matsumoto et al., 1991 ; Bradbury CD81 null mutation revealed normal T-and conven et al., 1992) . Co-ligation of this CD81-containing complex tional B-cell development, although CD19 expression and surface IgM/B-cell antigen receptor (BCR) resulted on B cells was dull and B-1 cells were reduced in in enhanced proliferation of B cells (Carter and Fearon, number. However, both T and B cells of mutant mice 1992). More recently, Boismenu et al. (1996) demonstrated exhibited strikingly enhanced proliferation in response that a monoclonal antibody (mAb), which could block to various types of stimuli. Interestingly, while proliferthymocyte development in a fetal thymus organ culture ative responses of T cells following T-cell antigen (FTOC) system, recognized CD81, concluding that CD81 receptor (TCR) engagement was enhanced in the is also essential for thymocyte development. They supabsence of CD81, B-cell proliferation in response to ported this possibility by showing that re-aggregation of B-cell antigen-receptor (BCR) cross-linking was fetal thymocytes with CD81-transfected CHO cells, but severely impaired. Despite these altered proliferative not non-transfected CHO cells, could induce thymocyte responses, both tyrosine phosphorylation and intramaturation. cellular calcium flux in response to cross-linking of cell Thus, the accumulating evidence indeed implicates the surface antigen receptors were normal in mutant mice, CD81 molecule as being involved broadly in several reflecting apparently normal initial signaling of antigen functions of lymphocytes. However, the roles of CD81 receptors. In conclusion, though CD81 is not essential in vivo still remain controversial. Therefore, we have for normal T-and conventional B-cell development, it generated mice incapable of making the CD81 molecule plays key roles in controlling lymphocyte homeostasis (CD81 -/-) by mutating the CD81 gene via homologous by regulating lymphocyte proliferation in distinct recombination in embryonic stem (ES) cells. Here we
Results Introduction
The recently discovered transmembrane 4 superfamily Generation of CD81 -/-mice A targeting vector was constructed by replacing all of (TM4SF, also called the tetraspans superfamily) proteins are cell surface molecules which are characterized by exons 3-7 and part of exon 8, which encode the second extracellular loop, the second to fourth membranethe presence of four hydrophobic domains, each presumed to be membrane-spanning (reviewed by Wright and spanning domains and the entire C-terminal intracellular domain (Andria et al., 1991) , with the neomycin resistance Tomlinson, 1994) . The TM4SF comprises up to 15 members that are differentially expressed on lymphocytes as gene ( Figure 1A ). Resulting CD81 -/-mice were born at the expected Mendelian frequency and raised normally well as on a variety of other cells types. It is well known that these TM4SF proteins are associated with various until at least 18 weeks of age under germ-free conditions. No obvious behavioral abnormalities were detected. The molecules, which include other TM4SF proteins themselves, on the cell surface (Angelisova et al., 1994;  Tedder abolished expression of CD81 in homozygous mutants was determined by Northern blotting ( Figure 1B ) and RTet al., 1994; Imai et al., 1995) . Rubinstein et al. (1996) recently reported that CD9, CD63, CD81 and CD82, PCR ( Figure 1C ) analysis either of spleen or thymus RNA, and the absence of CD81 protein production was members of the TM4SF, form a network connected to The NotI site in the targeting vector is artificial, derived from the original λ clone from which this pBSK subclone was derived. The probe DNA fragment for Southern blotting is indicated, as are the 12 and 4.2 kb XbaI hybridizable fragments in wild-type and mutant DNA, respectively. (B) Northern blotting. Fifteen μg of total spleen RNA either from wild-type (ϩ/ϩ) or mutant (-/-) littermates was hybridized with either CD81, CD19 or β-actin cDNA fragments. The same RNA filter was hybridized with each probe after stripping the previous probe. (C) RT-PCR for CD81 mRNA. CD81 gene expression in total thymus RNA of wild-type (ϩ/ϩ) or mutant (-/-) littermates was assessed by semi-quantitative RT-PCR. The amount of template cDNA for PCR corresponds to 50, 5, 0.5 or 0.05 ng from the left lane to the right lane. (D) Flow cytometric analysis of CD81 expression. Fresh spleen cells or LPS-blasts were stained for CD81 and B220 (by anti-CD81 mAb and FITC-conjugated secondary antibody, as well as PE-conjugated anti-B220). Histograms show the CD81 expression on B220-positive cells. In all panels, white histograms represent control staining of the indicated cells, stained only with secondary antibody and PE-anti-B220. All mAbs used here were obtained from Pharmingen. (E) Splenocytes were radioiodinated with Bolton-Hunter reagent, lysed in RIPA buffer, and the indicated proteins were immunoprecipitated. Immunoprecipitating antibodies were 2F7 (anti-CD81), M1/42.3.9.8 (anti-MHC class I), M5/114.15.2 (anti-MHC class II), and b-7-6 (anti-IgM). Migration of molecular mass markers is indicated in kDa. CD81 migrates as expected at~25 kDa. Though the level of class I MHC appears less in mutant mice, we could not detect any difference in the amount of class I MHC in separate experiments or when we used digitonin buffer lysis in the same experiment. Moreover, surface staining of class I MHC on thymocytes did not reveal any differences between wild-type and mutant mice (data not shown).
confirmed by cytofluorometric analysis of resting and from spleen cells ( Figure 1E ), thymocytes and thymic capsules (data not shown), using 2F7, a mAb against lipopolysaccharide (LPS)-activated splenic B cells ( Figure  1D ), as well as immunoprecipitation of CD81 protein CD81 (Boismenu et al., 1996) .
T-cell development peritoneal cavity cells. BM and spleen cells were doublestained with an antibody to the B cell-specific marker As previously mentioned, Boismenu et al. (1996) recently B220 in combination with anti-IgD, A4.1, Gr-1, antidemonstrated that the mAb 2F7, which we used for the MHC class II, anti-CD34, anti-CD5, anti-c-Kit, anti-CD43, protein analysis above, could block thymocyte developanti-CD25, anti-IL-7 receptor, anti-CD19, anti-CD23, antiment in a FTOC system and concluded that CD81 is CD40, anti-IgM and anti-CD21 mAbs, respectively (here essential for thymocyte development. Therefore, we examwe show CD19/B220 and IgM/B220 for BM cells, CD19/ ined T-cell development in CD81 -/-mice by cytofluoro-B220, CD21/B220, IgM/B220 and IgD/B220 for spleen metric analysis of the thymic and peripheral T-cell cells in Figure 3A and B). Despite the early expression compartments. Total thymocyte cell numbers were slightly and signaling potential of CD81, this analysis of BM cells increased in mutant animals as compared with those of from mutant animals revealed grossly normal development wild-type animals [1.2 Ϯ 0.5ϫ10 8 in ϩ/ϩ, 1.6 Ϯ 0.4ϫ10 8 and expansion of B-lineage cells, except for CD19 expresin -/-(n ϭ 10)]. Staining of CD4 and CD8 surface sion. As indicated in Figure 3A , mutant BM cells had markers provides a standard profile of thymocyte maturmuch duller cell surface expression of CD19 as compared ation. Typical staining profiles are presented in Figure 2A .
with wild-type BM cells, and there was a distinct compartSurprisingly, the CD4/CD8 profiles of CD81 -/-thymus ment characterized as B220 ϩ CD19 very low or negative . Splenic were indistinguishable from those of CD81 ϩ/ϩ thymus B cells from CD81 -/-mice were also CD19 dull (Figure (Figure 2A , upper panels). αβ T-cell antigen receptor 3B), although expression of other surface markers in the (TCR) and heat-stable antigen (HSA) expression were B-cell compartment, including CD21, and the antigen analyzed as maturation markers, but no differences were receptors IgM and IgD (and others; see above), was similar detected in CD81 -/-and CD81 ϩ/ϩ mice ( Figure 2A , to that in CD81 ϩ/ϩ mice ( Figure 3B ). Slightly decreased lower panels). Histologically, the structural integrity of the CD19 expression was detected even in heterozygote cortex/medulla in the thymic tissue was indistinguishable (CD81 ϩ/-) mice, in which CD19 expression was at an between mutant and wild-type animals (data not shown).
intermediate level between CD81 -/-and CD81 ϩ/ϩ mice We also analyzed CD25/CD44 and γδTCR expression in (data not shown). This low CD19 expression is not due the less mature CD4/CD8 double-negative (DN) populato down-regulated CD19 gene expression, because CD19 tion, but again no differences were observed (data not mRNA levels in CD81 -/-splenic B cells were indistinshown). We examined thymi from embryos at day 17.5 guishable from those in CD81 ϩ/ϩ splenic B cells (Figure when CD4/CD8 double-positive (DP) cells grossly develop 1B, Northern blot). These observations indicate that CD81 (Rodewald et al., 1994) , but again, there was no detectable might be involved in efficient cell surface expression of difference between CD81 -/-and CD81 ϩ/ϩ mice (Figure the CD19 molecule. However, one cannot exclude the 2B), indicating that maturation also occurs with normal possibility that lack of CD81 might alter the conformation kinetics in the mutant mice.
of the CD19/CD21/CD81/leu13 signaling complex, Total numbers of mature T cells in the lymph nodes resulting in loss of epitope recognized by the mAb. and spleen were comparable in the two types of mice, Unfortunately, it is difficult to examine this possibility and the relative contributions of the different populations because this is the only anti-CD19 mAb available for were essentially the same in mutant and wild-type animals. mouse B cells. Interestingly, CD21 expression was normal Expression patterns of the T-cell activation markers CD25 in the absence of CD81, although CD21, like CD19, and CD44 were also comparable in each population from comprises another element of this common signaling mutant and wild-type mice (data not shown).
complex on B cells. Similarly, it is reported that CD21 Positive and negative T-cell selection processes are expression was also not affected in CD19 -/-mice (Engel critical stages in the development of mature T cells Rickert et al., 1995) . can recognize foreign antigen in the context of self-MHC B-1 cells, which predominate in the peritoneal cavity, molecules yet are not reactive to endogenous self-antigen account for most serum IgM and are distinguished from peptides. These processes were examined by breeding the conventional (B-2) B cells by distinctive cell surface CD81 -/-mutation into transgenic mice expressing the expression of several markers, antigen specificity, signaling αβTCR against male antigen (H-Y). Thymocytes and growth properties (reviewed by Hardy and Hayakawa, expressing the H-Y-specific αβTCRs are positively 1994). Interestingly, B-1 cell formation in CD19 -/-mice selected in female H-2 b mice and negatively selected in was reported to be severely affected (Engel et al., 1995 ; male H-2 b mice (Kisielow et al., 1988; von Boehmer, Rickert et al., 1995) . In CD81 -/-mice, B-1 cells which 1990). In both females and males, thymocyte phenotypes exhibit the CD5 ϩ CD23 -IgM ϩ phenotype were also were comparable in CD81 -/-and CD81 ϩ/ϩ transgenic reduced in the peritoneal cavity, but not as drastically as H-2 b mice as defined by staining for CD4, CD8 and the reported for CD19 -/-mice ( Figure 3D ). This slight reductransgenic TCR α-chain ( Figure 2C ), indicating that both tion of B-1 cells in CD81 -/-mice could be explained by selection processes occur normally even in the absence the dull expression of CD19, although a direct effect of CD81.
through absence of CD81 cannot be excluded. The reducTogether, contrasting sharply with the reported results tion of serum IgM, which was reported in CD19 -/-mice, from organ culture experiments, these data strongly suggest was not detected in CD81 -/-mice. In addition, basal levels that T cells can develop normally in the absence of CD81 of every isotype of serum IgG were comparable in CD81 -/-molecules.
and CD81 ϩ/ϩ mice (data not shown).
B-cell development Enhanced T-cell proliferation responses Development of B-lineage cells was determined by cyto-
To determine peripheral T-cell functions, we evaluated proliferation of T cells from CD81 -/-and CD81 ϩ/ϩ mice fluorometric analysis of bone marrow (BM), spleen and in response to various stimuli. As shown in Figure 4A , T (ConA), a lectin which is known to activate T cells. In particular, at 1 μg/well of anti-CD3 mAb, the proliferation cells from CD81 -/-mice proliferated much better in response to either anti-CD3 mAb, which cross-links the of mutant T cells was~3-to 5-fold more than that of wild-type T cells. When T cells were co-stimulated with signaling chains of the TCR complex, or concanavalin A In all experiments, proliferation was assessed by duplicate of 50 ng/well of anti-CD28 mAb (s, ϩ/ϩ mice with anti-CD3 only;
[ 3 H]thymidine incorporation. All experiments were repeated with at d, -/-mice with anti-CD3 only; u, ϩ/ϩ mice with anti-CD3 ϩ antileast four pairs of CD81 ϩ/ϩ or -/-littermates. In all panels, each CD28; j, -/-mice with anti-CD3 ϩ anti-CD28), or (B) in MLR value represents the mean of all individual experiments and the ranges cultures by 2000 rad-irradiated spleen cells from B6.H-2 bm12 (bm12) of data are shown by bars. or MHC class I -/-class II -/-mice (I 0 II 0 ). In all experiments, proliferation was assessed by duplicate [ 3 H]thymidine incorporation. In MLRs, spontaneous proliferation-derived counts of corresponding cell numbers of lymph node cells (without APCs) were subtracted from each value. All experiments were repeated with at least four pairs of CD81 ϩ/ϩ or -/-littermates. In all panels, each value represents the mean of all results and the ranges of data are shown by bars.
( Figure 5A ). When compared with CD81 ϩ/ϩ B cells, their proliferation was increased by~2-to 3-fold in response to anti-CD40 stimulation and by 1.5-fold in response to LPS stimulation. In contrast, and very importantly, B-cell proliferation following surface IgM (BCR) cross-linking was impaired in CD81 -/-mice; it was in fact reduced by up to 40-50% when compared with CD81 ϩ/ϩ mice ( Figure 5B ).
T-cell-dependent B-cell activation T-cell-dependent B-cell activation was analyzed in vivo
by antibody production against a T-dependent antigen, keyhole limpet hemocyanin (KLH), and germinal center (GC) formation in swelling lymph nodes after immunizing with ovalbumin (OVA). Although grossly normal primary formation occurred in lymph nodes after immunization with OVA in CD81 -/-mice, although the numbers of GC spleen cells. Moreover, in immunoprecipitation from spleen cells, thymocytes and thymic capsules of CD81 -/-in the swelling lymph nodes were reduced in comparison with those in CD81 ϩ/ϩ mice (7-10 per section in ϩ/ϩ mice or CD81 ϩ/ϩ mice with the 2F7 mAb, no additional specific signals could be detected. versus 1-4 per section in -/-; data not shown).
Alternatively, one might expect that other TM4SF proteins which are also expressed in the thymus, such as Intact tyrosine phosphorylation and calcium flux following TCR or BCR engagement CD63 and CD82 (Nagira et al., 1994) , could take over the role of CD81 in thymocyte development. This possibility The differential proliferative responses of antigen receptors between T and B cells begged the question as to whether cannot be excluded. Thus, although we cannot definitively exclude the the absence of CD81 might directly modulate the signaling responsiveness of these receptors. We addressed this possibility that CD81 might have some roles in thymocyte development, thymocytes can develop normally even in question first by evaluating the tyrosine phosphorylation of cellular proteins in lymphocytes following cross-linking the absence of CD81 expression. of either BCR or the CD3 components of the TCR, expecting that this assay would reflect the initial signal CD81 potently regulates lymphocyte proliferation in a multipronged manner transduction capacities of the receptors (Robey and Allison, 1995) . Interestingly, in both cases, the pattern, CD81 originally was named as the target of anti-proliferative antigen (TAPA-1) because anti-CD81 antibodies degree and kinetics of phosphorylated substrates were essentially comparable in mutant and wild-type mice (data inhibit the proliferation of many lymphoid cell lines. It has been controversial, however, whether these anti-CD81 not shown). Thus, the tyrosine phosphorylation profiles from CD81 -/-mice did not mirror the decreased and antibodies induce negative signals to the target cells or interfere with the ligation of CD81 and its potential increased proliferative responses of B and T lymphocytes, respectively. Similarly, intracellular calcium flux following ligand(s). Our results show that CD81 acts as a negative or positive mediator of lymphocyte proliferation, dependantigen receptor cross-linking was also evaluated and, again, no detectable differences were observed in kinetics, ent on the types of stimuli. In the absence of CD81, lymphocytes exhibited enhanced proliferation in response magnitudes and dose responses (data not shown).
to CD3 cross-linking, ConA, allo-MHC, CD40 crosslinking or LPS, whereas proliferation in response to IgM/ Discussion BCR cross-linking was impaired. These diverse alterations of proliferation responses in T and B lymphocytes from
CD81 is not essential for early T-cell development
The potential involvement of CD81 in in vivo T-cell CD81 -/-mice suggest the involvement of CD81 in disparate signaling pathways for lymphocyte proliferation. development has drawn considerable interest following a recent report which implicated CD81 as an important Potential signaling mechanisms through CD81 are as yet undefined, because the three putative intracellular domains mediator of the pre-TCR-dependent development of DP thymocytes in in vitro FTOC experiments (Boismenu of this TM4SF protein are each only 10 amino acids long and contain no known motifs for signal transduction et al., 1996) . Two kinds of in vitro experiments were provided in that report to reach this conclusion. First, an (Andria et al., 1991) . Since CD81 is associated with various molecules on the cell surface (reviewed by Fearon, mAb, 2F7, which recognizes CD81 could block thymocyte development in an FTOC system. Second, addition of 1993; Tedder et al., 1994; Imai et al., 1995; Rubinstein et al., 1996; Szollosi et al., 1996) , one could envisage that CD81-transfected CHO cells allowed progression of DN precursor T cells to the DP developmental stage in a the individual complexes of CD81 and varied associated molecules may provide distinct intracellular signals in reaggregation culture system. Therefore, it was surprising that T cells developed normally in our CD81 -/-mice. different contexts. In this scheme, the multifaceted regulation of lymphocyte proliferation by CD81 might be due Having comparable developmental phenotypes in wildtype and mutant animals both in fetal and adult thymi, it to its varied coupling partners. Decreased proliferative response of CD81 -/-B cells appears unlikely that CD81 is required specifically for development of fetal thymocytes.
following IgM cross-linking could be due to the low CD19 expression, although the enhanced proliferation in response One could argue that the 2F7 mAb might affect in vitro thymocyte development by generating an inhibitory signal to anti-CD40 mAb or LPS cannot be explained in this manner. The effect of CD19 in B-cell proliferation is via cross-linking a distinct CD81-containing receptor complex on thymocytes. This argument might explain the still controversial because one group reported normal proliferation of B cells in response to IgM cross-linking results of the FTOC experiments in which 2F7 could block the thymocyte development, although it contrasts in CD19 -/-mice (Rickert et al., 1995) and another group reported an impaired proliferation response (Engel et al. , with the results of reaggregation experiments with CD81-transfected CHO cells, which implicated CD81-mediated 1995). Moreover, despite the impaired B-cell proliferation following IgM cross-linking, antibody production by B signals as a positive effector for early T-cell development.
An alternative explanation for the discrepancy in the cells against the T-dependent antigen in vivo was not strikingly affected in CD81 -/-mice, with only a partial results between the knockout mice and the organ cultures is that the mAb used in the blocking experiments might decrease in the production of the IgG 1 isotype. In contrast, it was severely impaired in CD19 -/-mice. Measuring a cross-react with other molecules which are essential for thymocyte development. This appears unlikely, however, T-dependent B cell response in CD81 -/-mice, however, might be complex. One could argue that the hyperbecause cytofluorometric analysis using the same mAb did not detect any cross-reactive surface protein on CD81 -/-responsiveness of T cells might compensate for the tions 457-437 in exon 5). MiyazakiT., Wolf,P., Tourne,S., Walzinger,C., Dierich,A., Barois,N., (Upstate Biotechnology) as previously described (Campbell et al., 1996) .
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